Skip to content

Climb Bio, Inc. CLYM Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.2×-0.6×
Amgen logo
AmgenAMGN
6.2×-3.0×
Vera Therapeutics logo
Vera TherapeuticsVERA
0.2×0.0×
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
0.0×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
0.0×
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Current ratio27.9×+13.6×

Where this comes from

Calculated from Climb Bio, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s debt-to-equity?
Climb Bio, Inc. (CLYM) reported debt-to-equity of 0× in Q1 2026.
How has Climb Bio, Inc.'s debt-to-equity changed year-over-year?
Climb Bio, Inc.'s debt-to-equity increased by 28.0% year-over-year, from 0× to 0×.
What is the long-term trend for Climb Bio, Inc.'s debt-to-equity?
Over 4 years (2021 to 2025), Climb Bio, Inc.'s debt-to-equity has grown at a -10.9% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.